Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

SmartArc-based volumetric modulated arc therapy for endometrial cancer: a dosimetric comparison with helical tomotherapy and intensity-modulated radiation therapy

Authors: Ruijie Yang, Junjie Wang, Shouping Xu, Hua Li

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

The purpose of the present study was to investigate the feasibility of using volumetric modulated arc therapy with SmartArc (VMAT-S) to achieve radiation delivery efficiency higher than that of intensity-modulated radiotherapy (IMRT) and helical tomotherapy (HT) when treating endometrial cancer, while maintaining plan quality.

Methods

Nine patients with endometrial cancer were retrospectively studied. Three plans per patient were generated for VMAT-S, IMRT and HT. The dose distributions for the planning target volume (PTV), organs at risk (OARs) and normal tissue were compared. The monitor units (MUs) and treatment delivery time were also evaluated.

Results

The average homogeneity index was 1.06, 1.10 and 1.07 for the VMAT-S, IMRT and HT plans, respectively. The V40 for the rectum, bladder and pelvis bone decreased by 9.0%, 3.0% and 3.0%, respectively, in the VMAT-S plan relative to the IMRT plan. The target coverage and sparing of OARs were comparable between the VMAT-S and HT plans. The average MU was 823, 1105 and 8403 for VMAT-S, IMRT and HT, respectively; the average delivery time was 2.6, 8.6 and 9.5 minutes, respectively.

Conclusions

For endometrial cancer, the VMAT-S plan provided comparable quality with significantly shorter delivery time and fewer MUs than with the IMRT and HT plans. In addition, more homogeneous PTV coverage and superior sparing of OARs in the medium to high dose region were observed in the VMAT-S relative to the IMRT plan.
Appendix
Available only for authorised users
Literature
1.
Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomized trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000, 355: 1404-1411. 10.1016/S0140-6736(00)02139-5.CrossRefPubMed
2.
Roberts JA, Zaino R, Keys H: A phase III randomized study of surgery vs surgery plus adjunctive radiation therapy in intermediate risk endometrial adenocarcinoma (GOG no. 99) [abstract]. Gynecol Oncol. 1998, 68: 135-
3.
Lujan AE, Mundt AJ, Yamada SD, Rotmensch J, Roeske JC: Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2003, 57: 516-521. 10.1016/S0360-3016(03)00521-2.CrossRefPubMed
4.
Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC: Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002, 52: 1330-1337. 10.1016/S0360-3016(01)02785-7.CrossRefPubMed
5.
Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, Mundt AJ: Intensity-modulated whole pelvis radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2000, 48: 1613-1621. 10.1016/S0360-3016(00)00771-9.CrossRefPubMed
6.
Lian J, Mackenzie M, Joseph K, Pervez N, Dundas G, Urtasun R, Pearcey R: Assessment of extended-field radiotherapy for stage IIIC endometrial cancer using three-dimensional conformal radiotherapy, intensity-modulated radiotherapy and helical tomotherapy. Int J Radiat Oncol Biol Phys. 2008, 70: 935-943. 10.1016/j.ijrobp.2007.10.021.CrossRefPubMed
7.
Hall EJ, Wuu CS: Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003, 56: 83-88. 10.1016/S0360-3016(03)00073-7.CrossRefPubMed
8.
Palma D, Vollans E, James K, Nakano S, Moiseenko V, Shaffer R, McKenzie M, Morris J, Otto K: Volumetric modulated arc therapy for delivery of prostate radiotherapy: Comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2008, 72: 996-1001. 10.1016/j.ijrobp.2008.02.047.CrossRefPubMed
9.
Van D, Van C, Van F, Crijns W, Coelmont A, De A, Lamers E, Geussens Y, Nuyts S, Van D, Van T, Vermorken JB, Gregoire V: RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. Radiat Oncol. 2013, 8: 37-10.1186/1748-717X-8-37.CrossRef
10.
Clivio A, Fogliata A, Franzetti-Pellanda A, Nicolini G, Vanetti E, Wyttenbach R, Cozzi L: Volumetric-modulated arc radiotherapy for carcinomas of the anal canal: A treatment planning comparison with fixed field IMRT. Radiother Oncol. 2009, 92: 118-124. 10.1016/j.radonc.2008.12.020.CrossRefPubMed
11.
Ong CL, Verbakel WF, Cuijpers JP, Slotman BJ, Lagerwaard FJ, Senan S: Stereotactic radiotherapy for peripheral lung tumors: A comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiother Oncol. 2010, 97: 437-442. 10.1016/j.radonc.2010.09.027.CrossRefPubMed
12.
Fogliata A, Clivio A, Nicolini G, Vanetti E, Cozzi L: Intensity modulation with photons for benign intracranial tumours: a planning comparison of volumetric single arc, helical arc and fixed gantry techniques. Radiother Oncol. 2008, 89: 254-262. 10.1016/j.radonc.2008.07.021.CrossRefPubMed
13.
Vanetti E, Clivio A, Nicolini G, Fogliata A, Ghosh-Laskar S, Agarwal JP, Upreti RR, Budrukkar A, Murthy V, Deshpande DD, Shrivastava SK, Dinshaw KA, Cozzi L: Volumetric modulated arc radiotherapy for carcinomas of the oro-pharynx, hypo-pharynx and larynx: A treatment planning comparison with fixed field IMRT. Radiother Oncol. 2009, 92: 111-117. 10.1016/j.radonc.2008.12.008.CrossRefPubMed
14.
Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Lyer R, Varia M, Winter K, Mundt AJ: Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008, 71: 428-434. 10.1016/j.ijrobp.2007.09.042.CrossRefPubMed
15.
Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ: Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006, 66: 1356-1365. 10.1016/j.ijrobp.2006.03.018.CrossRefPubMed
16.
Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B: Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008, 71: 1504-1510. 10.1016/j.ijrobp.2008.04.046.CrossRefPubMed
17.
Bzdusek K, Friberger H, Eriksson K, Hårdemark B, Robinson D, Kaus M: Development and evaluation of an efficient approach to volumetric arc therapy planning. Med Phys. 2009, 36: 2328-2339. 10.1118/1.3132234.CrossRefPubMed
18.
Cozzi L, Dinshaw KA, Shrivastava SK, Mahantshetty U, Engineer R, Deshpande DD, Jamema SV, Vanetti E, Clivio A, Nicolini G, Fogliata A: A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol. 2008, 89: 180-191. 10.1016/j.radonc.2008.06.013.CrossRefPubMed
19.
Baxter NN, Habermann EB, Tepper JE, Durham SB, Virnig BA: Risk of pelvic fractures in older women following pelvic irradiation. JAMA. 2005, 294: 2587-2593. 10.1001/jama.294.20.2587.CrossRefPubMed
20.
Pasquier D, Cavillon F, Lacornerie T, Touzeau C, Tresch E, Lartigau E: A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy. Int J Radiat Oncol Biol Phys. 2013, 85: 549-554. 10.1016/j.ijrobp.2012.03.046.CrossRefPubMed
21.
Davidson MT, Blake SJ, Batchelar DL, Cheung P, Mah K: Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys. 2011, 80: 1550-1558. 10.1016/j.ijrobp.2010.10.024.CrossRefPubMed
22.
D’Souza WD, Rosen II: Nontumor integral dose variation in conventional radiotherapy treatment planning. Med Phys. 2003, 30: 2065-2071. 10.1118/1.1591991.CrossRefPubMed
Metadata
Title
SmartArc-based volumetric modulated arc therapy for endometrial cancer: a dosimetric comparison with helical tomotherapy and intensity-modulated radiation therapy
Authors
Ruijie Yang
Junjie Wang
Shouping Xu
Hua Li
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-515

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivothrough suppression of PDGFR-β

Research article

“Unique trend” and “contradictory trend” in discrimination of primary synchronous lung cancer and metastatic lung cancer

Research article

Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis

Research article

Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign

Research article

Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors

Research article

Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits